A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer
Sponsor: Genmab A/S
Phase: 3
Disease: Recurrent platinum-sensitive epithelial ovarian cancer, High-grade serous epithelial ovarian carcinoma, High-grade endometrioid epithelial ovarian carcinoma, Primary peritoneal carcinoma, Fallopian tube carcinoma
EU trial number: 2025-524202-15-00
Population: Adults with recurrent platinum-sensitive high-grade serous or endometrioid epithelial ovarian cancer, including primary peritoneal or fallopian tube cancer, following one prior first-line platinum-based chemotherapy regimen. Recurrence or progression must occur more than 183 days after the last platinum dose.
Register Investigator Interest
Interested in offering this trial to suitable patients?